Fintech▲ 60

Medicus Pharma Clarifies SkinJect Phase 2 Data

Globenewswire·April 1, 2026 at 11:30 AM

Medicus Pharma Ltd. has provided clarification on the positive dataset from its SkinJect Phase 2 trial. The company is emphasizing the drug-driven efficacy observed in non-melanoma skin cancer treatments. This clarification aims to guide the interpretation of the topline results and reinforce the therapeutic potential of their approach. The focus remains on advancing the development of their innovative skin cancer treatment.

Medicus Pharma Clarifies SkinJect Phase 2 Data

Companies Balance AI Opportunities With Fear of Bubble

Sona Secures $45 Million for AI Platform Expansion

Tariffs Reshape Business Strategy One Year Later

eToro launches crypto trading in New York